Skip to main content

Principal Investigator:

Professor Lorcan McGarvey

 

Name of the Study:

BAY1817080 /18184 Cough: Two-part, double-blinded, placebo-controlled, randomised, parallel-group study (Part 2) two-way crossover administration of four different doses in patients with refractory chronic cough to assess safety, tolerability and efficacy for proof of concept.

       

What is the Research question/aim?

This trial is exploring the safety, tolerability and safety of BAY1817080 in Adult Participants with Chronic Cough. This study is a placebo-controlled, two-way crossover study meaning that all participants will receive both the study drug and the placebo. However, the order in which they receive them will be random, and at the time both the participant and study team will be blinded to which they are receiving.

 

What the Study involves: 

The Study involves 18 visits over approximately 12 weeks. Six of these visits may occur in the patient’s own home if they prefer.

 

PPI Involvement: 

No PPI involvement.

 

Who can take part in the Study?

Patients with chronic cough, aged over 18 years

 

Contact Information:

Professor Lorcan McGarvey

Respiratory Research Office

Ground Floor

Belfast City Hospital

Tower Block

 

Tel: 028 950 41136

Email: l.mcgarvey@qub.ac.uk

Location:

NI Clinical Research Facility,
U Floor, Belfast City Hospital,
Lisburn Road, Belfast, BT9 7AB

Tel:+44 (0)28 9504 0342
Email:NICRF@qub.ac.uk

Connect to the NICRF